Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin Corporation plc (NASDAQ:AMRN) presented new real-world data at the American Society of Nephrology Kidney Week 2020, highlighting the link between elevated triglyceride (TG) levels and increased cardiovascular (CV) risk. The analysis, conducted by the U.S. Department of Veterans Affairs, included 152,266 veterans with low-density lipoprotein (LDL)-cholesterol levels managed by statins. Results indicated that 29% of these patients had elevated TG levels and experienced higher rates of major adverse cardiovascular events, reinforcing TG levels as an independent risk factor for CV events in high-risk patients.
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on November 5, 2020, at 7:30 a.m. ET to discuss its third quarter 2020 financial results and provide an operational update. The call will be available on the company's investor relations website or via telephone. A replay will be accessible for two weeks after the call. Investors can submit questions via email until November 4, 2020, at 4:00 p.m. ET. Amarin focuses on improving cardiovascular health, with its lead product, VASCEPA, currently available by prescription in the U.S. and select countries.
Amarin Corporation plc (NASDAQ:AMRN) announced significant findings from the REDUCE-IT PCI study, presented at TCT Connect 2020. VASCEPA® (icosapent ethyl) demonstrated a 34% reduction in primary composite major adverse cardiovascular events (MACE) and a 39% reduction in total MACE for patients with a history of PCI. Absolute risk reductions were 8.5% and 5.4% for key secondary MACE endpoints. The study involved 3,408 patients, highlighting VASCEPA's role in reducing the need for invasive coronary revascularization procedures, which contribute to high healthcare costs.
Amarin Corporation plc (NASDAQ:AMRN) announced promising data from the REDUCE-IT PCI study at TCT Connect 2020, focusing on VASCEPA® (icosapent ethyl) and its impact on patients with a history of PCI. The analysis revealed a 34% reduction in primary composite major adverse cardiovascular events (MACE) and a 39% reduction in total MACE. Key secondary analyses showed similar reductions, with notable absolute risk reductions of 8.5% and 5.4%. These findings support VASCEPA’s role in mitigating risks associated with coronary revascularization, which poses significant healthcare costs.
Amarin Corporation plc (NASDAQ:AMRN) announced new data presentations at the virtual EAS Congress 2020, held from October 4 to October 7, 2020. The findings, presented by R. Preston Mason, Ph.D., focus on the mechanisms by which VASCEPA (icosapent ethyl) reduces cardiovascular risk. Two key presentations highlighted include:
- Improvement in nitric oxide bioavailability by eicosapentaenoic acid in endothelial cells.
- The modulation of membrane structure by EPA-containing phospholipids.
These insights aim to enhance understanding of VASCEPA's unique benefits in addressing cardiovascular disease.
Amarin Corporation (NASDAQ:AMRN) has announced that its CEO, John F. Thero, will present at the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020, from 11:20 to 11:50 a.m. ET. A live audio webcast of the presentation will be accessible on the company's investor relations website and available for 30 days post-event.
Amarin is focused on developing therapeutics for cardiovascular health, with its primary product, VASCEPA (icosapent ethyl), currently available in select countries. The company is seeking further regulatory approvals for VASCEPA in various regions.
Amarin Corporation provided an update on its patent litigation concerning the VASCEPA® (icosapent ethyl) capsule. The U.S. Court of Appeals upheld a ruling favoring two generic companies regarding their abbreviated new drug applications. Amarin plans to petition for an en banc review of this decision. Despite the setback, Amarin is pursuing additional regulatory approvals for VASCEPA in various international markets, including Europe and China, aiming for commercialization in early 2021. Amarin will maintain promotion efforts in the U.S. amidst expected limited generic competition.
Amarin Corporation presented significant findings at ESC Congress 2020 regarding VASCEPA, the first agent shown to induce coronary plaque regression in hypertriglyceridemic patients on statin therapy. The EVAPORATE trial revealed a 17% reduction in low attenuation plaque volume after 18 months of VASCEPA treatment. In the REDUCE-IT study, VASCEPA achieved statistical significance in reducing major adverse cardiovascular events across various patient subgroups. These results underscore VASCEPA's potential efficacy in mitigating cardiovascular risks and enhancing patient outcomes.
Amarin Corporation (NASDAQ:AMRN) announced positive results from the EVAPORATE trial, which evaluated the effects of VASCEPA on coronary plaque progression in patients treated with statins. The trial showed a significant 17% regression in low attenuation plaque (LAP) volume after 18 months compared with placebo. 80 patients participated, and although EVAPORATE was not powered for long-term outcomes, its findings reinforce VASCEPA's cardiovascular benefits demonstrated in the REDUCE-IT trial. While the study's sample size is a limitation, it provides valuable insights into VASCEPA's mechanisms.
Amarin Corporation announced new data on VASCEPA® (icosapent ethyl), to be presented at the ESC Congress 2020 from August 29 to September 1. Key presentations include the Late-Breaking Science session focusing on the EVAPORATE Study results, showing VASCEPA's effects on coronary atherosclerosis in patients on statin therapy. Other findings from the REDUCE-IT trials will also be shared, emphasizing data on ischemic events across different LDL cholesterol levels. This research underscores VASCEPA's potential in managing cardiovascular risks.
FAQ
What is the current stock price of Amarin (AMRN)?
What is the market cap of Amarin (AMRN)?
